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4 Results
There is currently no consensus on a model 
describing the endogenous glucose production 
(EGP) as a function of glucagon.
Recent studies suggest a multiplicative effect of 
insulin and of glucagon on EGP [1].
The pharmacodynamics (PD) model used in this 
study is mainly described by Hovorka et al. [2]. 
In a previous study, we extended the PD model to 
include the effects of insulin and of glucagon on 
EGP based on physiology and pre-clinical data [3].
Figure 1 shows examples of modelled EGP in 
response to varying glucagon concentrations and 
constant insulin concentrations at various levels. References
5 Conclusions
The PK model and the parameter distributions enable simulations of glucagon kinetics in 
healthy males weighing 77-92 kg. In the same population, the PD model and the parameter 
distributions enable simulations of the glucose-insulin-glucagon dynamics at the following 
plasma concentrations: glucagon (180-8000 pg/mL), insulin (1.2-81.9 mIU/L), and glucose 
(3.3-11.5 mmol/L). The models can be used for simulation of glucagon bolus strategies for 
treatment of hypoglycemia and for in silico simulation of dual-hormone artificial pancreas 
algorithms.
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The pharmacokinetics (PK) model is a one-compartment model with first order absorption. 
3 Methods
Parameter Unit Mean 95% Confidence Interval
Cb pg/mL 197 [155-239]
ClF mL/min 3689 [2343-5035]
k1 min
-1 0.023 [0.010-0.049]
k2 min
-1 0.082 [0.043-0.155]
CE50 pg/mL 407 [329-485]
Emax µmol/(kg·min) 38.8 [28.9-48.7]
F01 µmol/(kg·min) 10.5 [8.6-12.4]
k12 min
-1 0.031 [0.018-0.052]
ka1 min
-1 0.0034 *
ka2 min
-1 0.12 [0.11-0.13]
ka3 min
-1 0.015 [0.003-0.066]
SD min
-1 per mIU/L 0.0005 *
SE per mIU/L 0.04 [0.01-0.16]
ST min
-1 per mIU/L 0.0033 [0.0011-0.0096]
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1 Background
In healthy individuals, insulin and glucagon work in a complex fashion to maintain blood glucose 
levels within a narrow range. This regulation is distorted in patients with diabetes. The hepatic 
glucose response due to an elevated glucagon level depends on the current insulin concentration 
and thus endogenous glucose production (EGP) can not be modelled without knowledge of the 
concentration of both hormones in plasma. Furthermore, literature suggests an upper limit to EGP 
irrespective of glucagon levels. We build a simulation model of the glucose-insulin-glucagon 
dynamics in man including saturation effect of EGP. 
Ten healthy subjects received a 1 mg subcutaneous (SC) glucagon bolus (GlucaGen®). Plasma 
samples were collected until 300 minutes post dose and analyzed for glucagon, insulin, and 
glucose concentrations. All observations were used to fit a physiological model of the glucose-
insulin-glucagon dynamics using the Hovorka model with a novel multiplicative description of the 
effects of insulin and of glucagon on EGP. 
Bayesian estimation by Maximum a Posteriori using prior knowledge reported in literature was 
used to estimate the model parameters for each subject. Profile likelihood plots were used to 
investigate parameter identifiability. Unidentifiable parameters were fixed at their prior mean 
values.  
The new model enables simulations of the glucose-insulin-glucagon dynamics in humans at both 
low and high glucagon concentrations (180-8000 pg/mL) and physiologic insulin concentrations 
(1.2-81.9 mIU/L). The model can be used for simulation of glucagon bolus strategies for treatment 
of hypoglycemia and for in silico simulation of dual-hormone artificial pancreas algorithms.
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Table 1: Average PK and PD parameter estimates and 95% confidence intervals. *Fixed parameter.
Figure 2: PK model fit of glucagon (red), interpolated endogenous insulin (blue), and PD 
model fit of glucose with 95% confidence interval (teal) for each of the ten subjects. 
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Q1(t) and Q2(t) are the masses of glucose per bodyweight (μmol/kg) in the accessible and non-
accessible compartments. Glucose concentration (mmol/L) in the accessible compartment is Q1/V 
with V fixed at 160 mL/kg. I(t) is the insulin concentration (mIU/L) in the accessible compartment. 
xi(t) are remote effects of insulin (mIU/L). F01 is the non-insulin-dependent glucose flux. k12 and kai
are transfer rate constants. 
SD, SE, and ST are insulin sensitivities.
C(t) if the glucagon concentration 
(pg/mL) in the accessible 
compartment. Ib,y is the fixed basal 
insulin concentration (mIU/L) for 
subject y, and E0 is the minimum EGP 
fixed at 8 μmol/(kg·min). Emax is the 
maximum EGP at Ib,y. CE50 Is the 
glucagon concentration at half 
maximum EGP.
q1(t) and q2(t) are the masses of glucagon (pg) in the non-accessible and accessible 
compartments. k1 and k2 are transfer rate constants with k2 being greater than k1 since data 
demonstrate absorption limited elimination (flip-flop kinetics). Glucagon concentration in the 
accessible compartment is k2q2/ClF+Cb (pg/mL) where ClF is clearance uncorrected for 
bioavailability and Cb is basal plasma glucagon concentration. u(t) is the glucagon bolus (pg/min).
The PD model by Hovorka et al. [2] and our extension FIC(t) of the insulin and glucagon dependent 
EGP [3].
d𝒒𝟏(𝒕)
dt
= 𝒖 𝒕 − 𝒌𝟏𝒒𝟏(𝒕)
d𝒒𝟐(𝒕)
dt
= 𝒌𝟏𝒒𝟏(𝒕) − 𝒌𝟐𝒒𝟐(𝒕)
2 Data
Ten healthy male subjects weighing 84.5±7.4 kg (mean±2SD) received a 1 mg subcutaneous (SC) 
glucagon bolus (GlucaGen®). Plasma samples were collected pre dose and at nominal times 5, 10, 
15, 30, 45, 60, 75, 90, 105, 120, 180, 240, and 300 minutes post dose. Samples were analyzed for 
their concentrations of glucagon, insulin, and glucose using RIA test kit for glucagon (Euro 
Diagnostica), MSD human insulin kit (Meso Scale Diagnostics), and Hexokinase/glucose-6-P-
dehydrogenase test kit for glucose (Roche Diagnostics), respectively.
We used a maximum likelihood 
method to estimate individual PK 
model parameters, while a maximum 
a posteriori method with prior 
information [2, 3] was used to 
estimate individual PD model 
parameters [4]. Finally, we used 
profile likelihood analysis to find 
unidentifiable variables in the PD 
model and in the case of 
identifiability issues the parameters 
were fixed at their prior mean values. 
Figure 1: Full PK/PD model. The open arrow symbolizes SC input of glucagon. Solid arrows indicate mass trans-
fer. Dashed arrows indicate effect without mass transfer. Solid lines with dot endings indicate how concentrations 
are calculated. Plasma compartments are colored. A red dashed line surrounds the Hovorka et al. model [2].
Figure 1: EGP as modeled by the PD model.
